Serum concentration of zinc, copper, manganese and magnesium in patients with liver cirrhosis by Rahelić, Dario et al.
Coll. Antropol. 30 (2006) 3: 523–528
Original scientific paper
Serum Concentration of Zinc, Copper, Manganese
and Magnesium in Patients with Liver Cirrhosis
Dario Raheli}1, Milan Kujund`i}1, @eljko Romi}2, Kristina Brki}2 and Mladen Petrove~ki2
1 Division of Gastroenterology, Dubrava University Hospital, Zagreb, Croatia
2 Department of Laboratory Diagnostics, Dubrava University Hospital, Zagreb, Croatia
A B S T R A C T
The role of trace elements in the pathogenesis of liver cirrhosis and its complications is still not clearly understood.
Serum concentrations of zinc, copper, manganese and magnesium were determined in 105 patients with alcoholic liver
cirrhosis and 50 healthy subjects by means of plasma sequential spectrophotometer. Serum concentrations of zinc were
significantly lower (median 0.82 vs. 11.22 mol/L, p<0.001) in patients with liver cirrhosis in comparison to controls.
Serum concentrations of copper were significantly higher in patients with liver cirrhosis (median 21.56 vs. 13.09 mol/L,
p<0.001) as well as manganese (2.50 vs. 0.02 mol/L, p<0.001). The concentration of magnesium was not significantly
different between patients with liver cirrhosis and controls (0.94 vs. 0.88 mmol/L, p=0.132). There were no differences in
the concentrations of zinc, copper, manganese and magnesium between male and female patients with liver cirrhosis.
Only manganese concentration was significantly different between Child-Pugh groups (p=0.036). Zinc concentration
was significantly lower in patients with hepatic encephalopathy in comparison to cirrhotic patients without encepha-
lopathy (0.54 vs. 0.96 mol/L, p=0.002). The correction of trace elements concentrations might have a beneficial effect on
complications and maybe progression of liver cirrhosis. It would be recommendable to provide analysis of trace elements
as a routine.
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Introduction
The role of trace elements in pathogenesis of liver cir-
rhosis and its complications is still not clearly under-
stood. In fibrogenesis the initial occurrence is hepato-cel-
lular necrosis. In the early phase, inflammation cell
products, proteinases and reactive oxygen radicals, may
initiate hepato-cellular necrosis with consecutive releas-
ing of numerous cytokines. Following hepatic injury,
there is the increase in extracellular matrix, the activa-
tion of stellate cells, the increase in rough endoplasmatic
reticulum and expression of smooth muscle specific 	-
-actin1. Activated stellate cells are influenced by numer-
ous cytokines. Some of them have proliferative effect on
stellate cells while others stimulate fibrogenesis2.
Zinc, copper, manganese and magnesium are essential
trace elements whose role in liver cirrhosis and its com-
plications is still a matter of research. There are contrary
reports about their serum concentrations in patients
with liver cirrhosis. Zinc is associated with more than
300 enzymatic systems3. Zinc augments the natural de-
fense of reactive oxygen radicals by Zn-enzyme Cu-Zn
superoxide dismutase4. Zinc acts as an antioxidant, a
membrane and cytosceletal stabilizator, an anti-apop-
totic agens, an important co-factor in DNA synthesis, an
anti-inflammatory agens etc5.
Copper is an essential trace element which partici-
pates in many enzymatic reactions. Its most important
role copper has in redox processes. Reactive copper can
participate in liver damage directly or indirectly, through
Kupfer cell’s stimulation6. Scientists agree that copper’s
toxic effects are related to oxidative stress7.
Manganese is a structural part of arginase, which is
an important enzyme in the urea metabolism. Manga-
nese acts as an activator of numerous enzymes in Krebs
cycle, particularly in the decarboxilation process.
Magnesium is important for the protein synthesis, en-
zyme activation, oxidative phosphorilation, renal potas-
sium and hydrogen exchange etc.
Since zinc, copper, manganese and magnesium have a
possible role in the pathogenesis of cirrhotic complica-
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tions, the aim of this study was to investigate the serum
concentrations of mentioned trace elements in patients
with liver cirrhosis and compared them with concentra-
tions in controls.
Material and Methods
Subjects
The study included 105 patients with diagnosed liver
cirrhosis of ethylic etiology who were hospitalized from
2000 to 2005 in the Division of Gastroenterology at
Dubrava University Hospital, with median age 55 years.
Seventy eight (74%) of them were male and twenty seven
(26%) were female. According to the Child-Pugh classifi-
cation patients with liver cirrhosis were divided in Child-
-Pugh A, B and C group. There were 35 subjects in every
Child-Pugh group.
Inclusion criteria were liver cirrhosis (diagnosed by
anamnestic data of alcohol consumption, laboratory and
pathohistological findings, negative markers of viral hep-
atitis and normal values of ceruloplasmine), ability to
sign the Informed consent and age 18 to 70.
Exclusion criteria were vegetarianism, Wilson's dise-
ase, malign disease, acute liver failure, impaired renal
function (creatinine clearance <60 ml/min), multiorga-
nic failure and inability to sign the Informed consent.
The control group consisted of 50 healthy subjects
(median age 52 years) who were performed laboratory
analysis as part of systematic medical examinations.
There were 35 (70%) males and 15 (30%) females.
The Informed consent was obtained from all study
subjects. The study protocol was approved by the Ethics
Committee of Dubrava University Hospital. The protocol
was carried out in accordance with the ethics guidelines
of the Helsinki Declaration.
Methods
Blood samples were collected without anticoagulans
and serum was stored in a freezer on –20°C until process-
ing. In processing 1 ml of serum was taken, 1.5 ml of con-
centrated nitric acid and 0.5 ml 30% H2O2 were added on
account of the digestion. After the digestion the sample
was cooling for 20 minutes. The solution was transferred
into a 10 ml container and was supplemented with ultra
clean water. The concentrations of trace elements were
determined by means of plasma sequential spectropho-
tometer TraceScan (Thermo Jarrell Ash, USA). Data
were presented with median and 5–95 percentile range
and compared using Wilcoxon and Kruskal-Wallis non-
-parametric tests. Statistics was done using MedCalc
software (MedCalc Software, Mariakerke, Belgium). Only
p<0.05 was considered significant.
Results
The serum levels of zinc, copper, manganese and mag-
nesium in patients with liver cirrhosis and controls are
presented in Table 1. The levels of zinc were significantly
lower in patients with liver cirrhosis in comparison to
controls (0.82 
mol/L vs. 11.22 
mol/L, p<0.001). The se-
rum concentration of copper was significantly higher in
patients with liver cirrhosis in comparison to controls
(21.56 
mol/L vs. 13.09 
mol/L, p<0.001) as well as man-
ganese concentration (2.50 
mol/L vs. 0.02 
mol/L, p<
0.001). The concentration of magnesium was not signifi-
cantly different between patients with liver cirrhosis and
controls (Table 1, p=0.132). There were no differences in
the concentrations of zinc, copper, manganese and mag-
nesium between male and female patients with liver cir-
rhosis (Table 2).
The data in Table 3 show that the serum levels of
manganese were significantly different between Child-
-Pugh groups (H=9.21, p=0.036). An additional analysis
showed that the serum levels of manganese were signifi-
cantly higher in patients with Child-Pugh C liver cirrho-
sis (6.30 
mol/L) in comparison to patients with Child-
-Pugh A (2.00 
mol/L, z=–3.09, p=0.002) and B liver
cirrhosis (2.10 
mol/L, z=–2.06, p=0.039). The concen-
trations of zinc, copper, and magnesium did not differ
significantly between Child-Pugh groups (Table 3).
The serum concentrations of zinc, copper, manganese
and magnesium in cirrhotic patients with and without
hepatic encephalopathy are represented in Table 4. The
concentration of zinc was significantly lower in patients
with hepatic encephalopathy in comparison to cirrhotic
patients without encephalopathy (0.54 
mol/L vs. 0.96

mol/L, p=0.002). There were no differences in serum
concentrations of other trace elements between patients
with or without encephalopathy. The serum concentra-
tions of zinc, copper, manganese and magnesium in cir-
rhotic patients with and without ascites are represented
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TABLE 1
SERUM CONCENTRATIONS OF ZINC, COPPER, MANGANESE AND MAGNESIUM IN PATIENTS
WITH LIVER CIRRHOSIS AND CONTROLS
Trace elements
Subjects (N=105) median
and 5–95 percentiles
Controls (N=50) median
and 5–95 percentiles
Statistics
z p
Zinc (
mol/L) 0.82 (0.24–1.74) 11.22 (9.23–15.10) 10.05 <0.001
Copper (
mol/L) 21.56 (11.17–30.60) 13.09 (11.17–19.95) –7,66 <0.001
Manganese (
mol/L) 2.50 (0.01–29.65) 0.02 (0.01–0.40) –8,21 <0.001
Magnesium (mmol/L) 0.94 (0.63–1.36) 0.88 (0.56–1.12) –1.51 0.132
in Table 5. Only manganese concentration was signifi-
cantly different between patients with and without ascit-
es. Namely, serum manganese concentration was higher
in cirrhotic patients with ascites in comparison to cir-
rhotic patients without ascites (4.10 
mol/L vs. 1.80

mol/L, p<0.001).
Discussion
Mechanisms linked on ethanol metabolism, especially
oxidative stress, redox potentials and acetaldehyde, par-
ticipate in the emergence of liver damage. Trace ele-
ments play an important role in oxidative stress and re-
dox potentials. A possible role of zinc, copper, manganese
and magnesium in pathogenesis of liver cirrhosis and its
complications is still subject of researches.
In our research the serum levels of zinc were signifi-
cantly lower in patients with liver cirrhosis in compari-
son to controls (Table 1, median 0.82 
mol/L in patient
with liver cirrhosis and 11.22 
mol/L in controls, p<
0.001). The results confirm Kugelmans’ research8, who
explained low zinc levels with low ingestion due to pro-
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TABLE 4
SERUM CONCENTRATIONS OF TRACE ELEMENTS IN CIRRHOTIC PATIENTS WITH AND WITHOUT HEPATIC ENCEPHALOPATHY
Trace elements
Without encephalopathy
(N=83) median and 5–95
percentiles
With encephalopathy
(N=22) median and 5–95
percentiles
Statistics
z p
Zinc (
mol/L) 0.96 (0.25–1.77) 0.54 (0.19–1.11) –3.07 0.002
Copper (
mol/L) 21.56 (13.07–31.43) 21.31 (9.85–29.31) –1.21 0.227
Manganese (
mol/L) 2.20 (0.01–31.38) 4.90 (0.01–26.94) 0.66 0.506
Magnesium (mmol/L) 0.95 (0.63–1.36) 0.90 (0.53–1.37) –1.72 0.086
TABLE 5
SERUM CONCENTRATIONS OF TRACE ELEMENTS IN CIRRHOTIC PATIENTS WITH AND WITHOUT ASCITES
Trace elements
Without ascites (N=45)
median and 5–95 percentiles
With ascites (N=60)
median and 5–95 percentiles
Statistics
z p
Zinc (
mol/L) 0.97 (0.36–1.57) 0.69 (0.18–1.78) 1.77 0.077
Copper (
mol/L) 20.25 (11.84–30.47) 22.42 (10.74–30.82) –0.28 0.778
Manganese (
mol/L) 1.80 (0.01–11.20) 4.10 (0.01–31.80) –3.43 <0.001
Magnesium (mmol/L) 0.92 (0.64–1.13) 0.94 (0.54–1.46) –0.58 0.564
TABLE 2
SERUM CONCENTRATIONS OF ZINC, COPPER, MANGANESE AND MAGNESIUM
IN MALE AND FEMALE PATIENTS WITH LIVER CIRRHOSIS
Trace elements
Male (N=78) median
and 5–95 percentiles
Female (N=27) median
and 5–95 percentiles
Statistics
z p
Zinc (
mol/L) 0.84 (0.25–1.70) 0.74 (0.20–1.99) –0.32 0.750
Copper (
mol/L) 21.18 (9.86–30.07) 23.56 (15.49–32.12) 1.58 0.113
Manganese (
mol/L) 2.10 (0.01–31.20) 3.70 (0.08–29.55) 1.45 0.146
Magnesium (mmol/L) 0.96 (0.58–1.40) 0.88 (0.71–1.36) –1.05 0.293
TABLE 3
SERUM CONCENTRATIONS OF TRACE ELEMENTS IN CHILD-PUGH GROUPS
Trace elements
Child-Pugh A (N=35)
median and 5–95
percentiles
Child-Pugh B (N=35)
median and 5–95
percentiles
Child-Pugh C (N=35)
median and 5–95
percentiles
Statistics
H p
Zinc(
mol/L) 1.06 (0.38–1.49) 0.78 (0.26–1.94) 0.54 (0.14–1.45) 19.24 0.053
Copper (
mol/L) 19.98 (13.75–29.84) 22.30 (10.51–31.65) 23.20 (9.75–29.76) 1.00 0.608
Manganese (
mol/L) 2.00 (0.12–9.42) 2.10 (0.01–27.62) 6.30 (0.01–35.75) 9.21 0.036
Magnesium (mmol/L) 0.93 (0.65–1.18) 0.96 (0.65–1.38) 0.88 (0.40–1.53) 5.34 0.084
tein reluctance, increased loss in gastroenterological sys-
tem due to diarrhea or intestinal malabsorption and in-
creased urinary losses. The assumption is also based on
the research of McClain9 and Extremera10. Protein defi-
ciency occurs frequently due to poor dietary intake. Our
results confirm findings of decreased serum concentra-
tions of zinc in patients with liver cirrhosis. Possible ex-
planations for the decreased zinc levels in cirrhotic pa-
tients are mentioned above.
In Celik’s research11 the decrease in both serum and
ascites zinc content was found in patients with liver cir-
rhosis. The interaction between zinc and copper in their
intestinal absorption and their competition for binding
sites on the carrier proteins and cellular uptake may be
regulators of their homeostasis. Maybe this can explain
inverse concentrations of zinc and copper. Zinc binds on
albumin, transferrin and metalloproteins in the cell, so
relative concentrations of these proteins might regulate
the serum concentration of zinc11,12.
The serum copper content was found significantly in-
creased in patients with liver cirrhosis in comparison to
the control group (Table 1, median 21.56 
mol/L in pa-
tient with liver cirrhosis and 13.09 
mol/L in controls,
p<0.001). It could be explained with copper’s role in the
redox process. Redox cycling between Cu2+ and Cu1+ can
catalyze the production of toxic hydroxyl radicals13,14. It
is a well known fact that redox processes and oxidative
stress play an important role in the pathogenesis of liver
cirrhosis.
Serum concentrations of manganese were significant-
ly higher in cirrhotic patients in comparison to controls
(Table 1, median 2.50 
mol/L in cirrhotic patients and
0.02 
mol/L in controls, p<0.001). Higher serum levels of
manganese in Krieger’s research15 as well as in research
of Layrargues and co.16 were also found in cirrhotic pa-
tients.
Moscarello17 did not find any significant difference in
the concentrations of manganese between cirrhotic pa-
tients and controls. After all, it seems that serum levels
of manganese are higher in patients with liver cirrhosis
than in healthy people. Manganese is secreted in bile so
the concentration of manganese increases in cholestatic
liver disease, which could be one of the possible explana-
tions why manganese accumulation is common in liver
cirrhosis15,18.
It has been suggested that a possible mechanism re-
sponsible for manganese accumulation in the pallidum of
patients include a decrease in biliary excretion and in-
creased systemic availability due to portosystemic shunt-
ing.
Intrahepatic shunting or portosystemic shunting also
have an additional effect on manganese accumulation. In
the study of Rose et al.19 pallidal manganese concentra-
tions were the highest in shunted rats, which confirms
that shunting is a major determinant of manganese accu-
mulation in the brain. Manganese accumulation in the
brain was confirmed by several clinical studies15,19–21.
The difference between serum concentrations of mag-
nesium in cirrhotic patients and controls was not signifi-
cant (Table 1, median 0.94 mmol/L in cirrhotic patients
and 0.88 mmol/L in controls, p= 0.132). Results are op-
posite to Kosch’s research22. In that research serum lev-
els of magnesium were lower in patients with liver cir-
rhosis in comparison to patients with liver steatosis and
controls. In addition, the research of Rocchi23 and Suzu-
ki24 confirmed the same. Our research did not confirm
lower concentrations of magnesium in patients with liver
cirrhosis. That partially could be explained with influ-
ence of spironolactone on magnesium levels. Namely, in
Stergiou’s research25 spironolactone in health subjects
decreased urine excretion of magnesium and in cirrhotic
patients antagonized magnesiuric effect of furosemide.
Our patients with liver cirrhosis mostly have spirono-
lactone in their standard therapy, but there were no dif-
ferences between patients who were taking spironolac-
tone and those who were not taking spironolactone.
There was a slight decrease in serum zinc concentra-
tions in patients with more severe clinical state of liver
cirrhosis according to Child-Pugh classification but these
differences in our research were not significant.
As zinc is bound to albumin in the serum, it has been
thought that the serum zinc concentration would decrease
with advancing grades of hepatic fibrosis26. Yoshida27
found that patients with decompensated liver cirrhosis
have lower levels of zinc than patients with compensated
cirrhosis. However, in Hatano’s research26 serum zinc
levels did not differ significantly between grades of he-
patic fibrosis.
Copper levels in our research were similar in all three
Child-Pugh groups (Table 3), as well as in Hatano’s re-
search.
Serum levels of manganese were higher in patients
with Child-Pugh C liver cirrhosis in comparison to those
in Child-Pugh A and B cirrhosis. Our results are contrary
to Spahr’s research21 who found similar concentrations
of manganese in all three Child-Pugh groups. It seems
that manganese concentrations are higher in patients
with severe liver cirrhosis possible due to the advanced
intrahepatic and portosystemic shunting.
In our study magnesium levels were similar in all
Child-Pugh groups. Moscarella’s research17 also confirms
similar levels in compensated and decompensated liver
cirrhosis. However, Wang28 found that magnesium defi-
ciency occurs more frequently in severe liver disease.
Significantly lower zinc levels were found in cirrhotic
patients with hepatic encephalopathy (Table 4, median
0.54 
mol/L in patients with encephalopathy and 0.96

mol/L without encephalopathy, p= 0.002), which was
confirmed in other studies29,30. There are some findings
that zinc supplementation can cause increased releasing
of glutamine from sceletal muscle and also activate glu-
tamine synthetasis, which can decrease the level of am-
monia and improve hepatic encephalopathy29. That can
be explained with the fact that zinc supplementation in-
creases the hepatic activity of ornithine transcarbamoy-
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lase, key enzyme of the urea cycle, which consecutively
increases urea formation and decreases ammonia levels30.
The rationale for use of zinc is also its ability to induce
intestinal and hepatic metallothionein synthesis. Zinc
decreases copper absorption by increasing the formation
of Cu-metallothionein in intestinal epithelial cells31. How-
ever, Riggio found that short-term zinc supplementation
has no influence on hepatic encephalopathy32.
Considering all, zinc supplementation could have a
positive influence on hepatic encephalopathy but before
the implementation of this result in the treatment, fur-
ther researches are necessary.
The levels of manganese were not significantly differ-
ent between patients with liver cirrhosis and hepatic
encephalopathy and patients without encephalopathy
(Table 4, p=0.506), which is opposite to the researches of
Hauser20 and Krieger15. They found increased concentra-
tions of manganese and suggested a beneficial effect of
prevention of accumulation or decreasing manganese
concentration in patients with liver cirrhosis. Rose19 and
Layrargues16 found increased concentrations of manga-
nese in basal ganglia of cirrhotic patients in comparison
to controls.
Manganese concentrations in our research were sig-
nificantly higher in cirrhotic patients with ascites in
comparison to those without ascites (Table 5, median
4.10 
mol/L in patients with ascites and 1.80 
mol/L in
patients without ascites, p<0.001). The levels of zinc,
copper and magnesium were within reference range. Our
results are contrary to the research of Pasqualetti33 who
found significantly lower magnesium concentrations in
patients with ascites. Therefore, it is necessary to re-
search the possible role of manganese in emergence of
ascites in patients with liver cirrhosis.
Finally, decreased serum concentrations of zinc and
increased levels of manganese in patients with liver cir-
rhosis could have an important role in the pathogenesis
of liver cirrhosis and its complications, especially in he-
patic encephalopathy. The supplementation of zinc could
improve hepatic encephalopathy. The decrease in manga-
nese levels could also have a beneficial effect on the neu-
rological status in patients with liver cirrhosis and hepatic
encephalopathy. Increased concentrations of manganese
in cirrhotic patients with ascites inspire further research-
es about a possible role of manganese in the pathogenesis
of ascites in patients with liver cirrhosis. Maybe, decreas-
ing of manganese levels might also have beneficial effect
on prevention or volume of ascites.
Considering all that, the correction of serum trace ele-
ments concentrations would have a beneficial effect on
some complications of liver cirrhosis and maybe on pro-
gression of the disease, so it would be recommendable to
provide laboratory analysis of trace elements as a rou-
tine.
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SERUMSKE KONCENTRACIJE CINKA, BAKRA, MANGANA I MAGNEZIJA
U BOLESNIKA S JETRENOM CIROZOM
S A @ E T A K
Cilj istra`ivanja bio je odrediti serumske koncentracije cinka, bakra, mangana i magnezija u bolesnika s jetrenom
cirozom i usporediti ih s koncentracijama u zdravih ispitanika. Serumske koncentracije navedenih elemenata u tra-
govima bile su odre|ivane u 105 bolesnika s jetrenom cirozom i 50 ispitanika kontrolne skupine pomo}u plazma sek-
vencijskog spektrofotometra. Serumske koncentracije cinka bile su statisti~ki zna~ajno ni`e u bolesnika s jetrenom
cirozom u odnosu na ispitanike kontrolne skupine (medijan 0.82 prema 11.22 
mol/L, p<0.001). Koncentracije bakra
bile su zna~ajno povi{ene u bolesnika s jetrenom cirozom u odnosu na kontrolnu skupinu (medijan 21.56 prema 13.09

mol/L, p<0.001) kao i koncentracije mangana (medijan 2.50 prema 0.02 
mol/L, p<0.001). Koncentracije magnezija
nisu bile zna~ajno razli~ite izme|u bolesnika s jetrenom cirozom i ispitanika kontrolne skupine (p=0.132). Koncen-
tracije cinka, bakra, mangana i magnezija nisu bile razli~ite u mu{kih i `enskih bolesnika s jetrenom cirozom. Serumske
koncentracije mangana bile su statisti~ki zna~ajno razli~ite izme|u Child-Pughovih skupina (p=0.036), dok koncen-
tracije cinka, bakra i magnezija nisu bile zna~ajno razli~ite izme|u Child-Pughovih skupina. Zna~ajno ni`e serumske
koncentracije cinka prona|ene su u bolesnika s jetrenom cirozom i portalnom encefalopatijom u usporedbi s boles-
nicima bez portalne encefalopatije (0.54 prema 0.96 
mol/L, p=0.002). Korekcija koncentracija elemenata u tragovima
mogla bi imati pozitivan u~inak na komplikacije a mogu}e i tijek jetrene ciroze, stoga bi bilo preporu~ljivo u bolesnika s
jetrenom cirozom odre|ivati serumske koncentracije elemenata u tragovima kao dio rutinske laboratorijske obrade.
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